Study Summary
This trial will assess the effectiveness of cabozantinib in patients with recurrent liver cancer who have previously received a liver transplant.
- Liver Cancer
- Recurrent Cancer
- Liver Transplant
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 3 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Cabozantinib
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Cabozantinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 15 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- D’Alessio, Antonio, Antonella Cammarota, Maria Giuseppina Prete, Tiziana Pressiani, and Lorenza Rimassa. 2021. “The Evolving Treatment Paradigm of Advanced Hepatocellular Carcinoma: Putting All the Pieces Back Together”. Current Opinion in Oncology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/cco.0000000000000744.
- Azhie, Amirhossein, Robert C Grant, Michael Herman, Lisa Wang, Jennifer J Knox, and Mamatha Bhat. 2022. “Phase II Clinical Trial of Cabozantinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation”. Future Oncology. Future Medicine Ltd. doi:10.2217/fon-2021-1635.
- Azhie, Amirhossein, Robert C Grant, Michael Herman, Lisa Wang, Jennifer J Knox, and Mamatha Bhat. 2022. “Phase II Clinical Trial of Cabozantinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation”. Future Oncology. Future Medicine Ltd. doi:10.2217/fon-2021-1635.
- Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncol. 2022 Jun;18(18):2173-2191. doi: 10.2217/fon-2021-1635. Epub 2022 Mar 15.
- 2020. "Cabozantinib to Treat Recurrent Liver Cancer Post Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04204850.
Frequently Asked Questions
How many people total are participating in this experiment?
"Yes, this is an active trial that was posted on August 7th, 2020 and updated most recently on April 11th, 2021. They are looking for 20 individuals at a single site." - Anonymous Online Contributor
Are there any current openings for volunteers in this experiment?
"The clinical trial is currently looking for 20 more participants and is enrolling at 1 site. The information was found on clinicaltrials.gov, where the study was originally posted on 8/7/2020 and edited on 4/11/2021." - Anonymous Online Contributor
Are there other ongoing research projects that investigate Cabozantinib?
"At the moment, there are 116 ongoing studies looking into the effects of cabozantinib. Of these, 13 are in phase 3. Many of the trials for cabozantinib are taking place in Cordoba and Calabria, but there are 7151 clinical trial sites across the globe." - Anonymous Online Contributor
Is there a large margin of safety for Cabozantinib?
"There is some data supporting Cabozantinib's safety, but none showing that it is an effective treatment. It received a score of 2." - Anonymous Online Contributor
Does this research have any predecessors?
"First researched in 2012, Cabozantinib has had 86 patients in its initial study. After the first Phase 2 trial, it was approved for use and there are currently 116 live studies being conducted across 1375 cities and 46 countries." - Anonymous Online Contributor
What are the standard applications for Cabozantinib?
"Patients who have received anti-vegf treatment, those with advanced renal cell carcinoma (arcc), and patients with adrenal medulla can all be treated using Cabozantinib." - Anonymous Online Contributor